These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 35114759

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
    Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.
    Eur J Cancer; 2012 Nov; 48(16):3082-92. PubMed ID: 22975218
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, Sendo T.
    Biol Pharm Bull; 2015 Nov; 38(12):1850-5. PubMed ID: 26632176
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of Periodontal Space Widening in Patients with Antiresorptive Drug-related Osteonecrosis of the Jaws (ARONJ) on Panoramic Radiographs.
    Assaf AT, Amberg V, Smeets R, Wikner J, Hanken H, Semmusch J, Ewald F, Rashad A, Friedrich RE.
    Anticancer Res; 2018 Sep; 38(9):5305-5314. PubMed ID: 30194182
    [Abstract] [Full Text] [Related]

  • 26. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
    Takaoka K, Kishimoto H.
    Nihon Yakurigaku Zasshi; 2019 Sep; 153(1):22-27. PubMed ID: 30643088
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T.
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.
    Laimer J, Hechenberger M, Müller D, Walch B, Kolk A, Schnabl D, Schomaker M, Bruckmoser E.
    Future Oncol; 2021 Jul; 17(21):2705-2711. PubMed ID: 33880956
    [Abstract] [Full Text] [Related]

  • 31. Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
    Flores IL, dos Santos-Silva AR, Della Coletta R, Vargas PA, Lopes MA.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Mar; 117(3):e264-8. PubMed ID: 24528798
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
    Wei LY, Kok SH, Lee YC, Chiu WY, Wang JJ, Cheng SJ, Chang HH, Lee JJ.
    J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Bisphosphonates and other bone agents for breast cancer.
    Wong MH, Stockler MR, Pavlakis N.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD003474. PubMed ID: 22336790
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.
    Lancet; 2011 Mar 05; 377(9768):813-22. PubMed ID: 21353695
    [Abstract] [Full Text] [Related]

  • 38. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.
    Eur Urol; 2014 Feb 05; 65(2):278-86. PubMed ID: 23706567
    [Abstract] [Full Text] [Related]

  • 39. Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries.
    Taguchi A, Shiraki M, Morrison A, Khan AA.
    Osteoporos Sarcopenia; 2017 Jun 05; 3(2):64-74. PubMed ID: 30775507
    [Abstract] [Full Text] [Related]

  • 40. Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis.
    Fujieda Y, Atsumi T.
    J Bone Miner Metab; 2020 Sep 05; 38(5):739-741. PubMed ID: 32591907
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.